

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 April 2025 (10.04.2025)



(10) International Publication Number
WO 2025/076291 A1

(51) International Patent Classification:
C12N 9/22 (2006.01) C12N 15/55 (2006.01)

(21) International Application Number:
PCT/US2024/049884

(22) International Filing Date:
04 October 2024 (04.10.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/588,636 06 October 2023 (06.10.2023) US

(71) Applicant: **BLUEROCK THERAPEUTICS LP**
[US/US]; 238 Main Street, 3rd Floor, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **RAO, Timsi**; c/o BlueRock Therapeutics LP, 238 Main Street, 3rd Floor, Cambridge, Massachusetts 02142 (US). **MUNZER, Jon Scott**; c/o BlueRock Therapeutics LP, 238 Main Street, 3rd Floor, Cambridge, Massachusetts 02142 (US). **NURANI, Mohamadadnan**; c/o BlueRock Therapeutics LP, 238 Main Street, 3rd Floor, Cambridge, Massachusetts 02142 (US).

(74) Agent: **ABU-SHAAR, Muna et al.**; Biospark Intellectual Property Law, 1 Broadway, 14th Floor, Cambridge, Massachusetts 02142 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: ENGINEERED TYPE V RNA PROGRAMMABLE ENDONUCLEASES AND THEIR USES




FIG.8

(57) Abstract: The present disclosure provides engineered Type V endonucleases suitable for editing eukaryotic genomic DNA, as well as methods of producing the nucleases, systems comprising the nucleases, as well as methods of using the nucleases and systems to edit eukaryotic genomic DNA.

[Continued on next page]

WO 2025/076291 A1

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))